Daunorubicin

Jun 14, 2019

Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019

May 16, 2019

Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

Nov 07, 2018

National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML)

Sep 11, 2018

Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch

Aug 27, 2018

Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jul 19, 2018

Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Apr 13, 2018

Tolero Pharmaceuticals to Present Preclinical Data Supporting Apoptosis-Inducing Activity of Alvocidib in Acute Myeloid Leukemia

Feb 08, 2018

National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos(TM) (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology

Nov 03, 2017

Jazz Pharmaceuticals Submits Vyxeos(TM) Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia